Michael O Brien

Michael O'Brien is a Vice President at Athyrium Capital Management, a New York–based specialty asset manager formed in 2008 to focus exclusively on the global healthcare and life sciences sector. He joined the firm in 2018. At Athyrium he concentrates on growth-stage investments across healthcare services and technology, with a stated emphasis on pharma services and value-based care delivery.

Prior to Athyrium, O'Brien worked as an investment banking analyst in the Healthcare group at Guggenheim Partners, where he advised on a number of M&A transactions involving biotech and pharmaceutical companies. That sell-side healthcare advisory background informs his current work sourcing and structuring private investments in the sector.

He holds a B.S. in Economics from The Wharton School at the University of Pennsylvania.

Athyrium itself advises funds with over $4.6 billion of committed capital and invests across royalties, structured credit, equity, and special situations in healthcare. The firm has a long-running partnership with Neuberger Berman, with which it has closed multiple multi-billion-dollar healthcare funds (a $1.2B fund and later a $2B fund). O'Brien operates within this credit- and structured-investment-oriented platform rather than as an independent angel investor.

• Invests in growth-stage healthcare companies — typically revenue-generating businesses, not early seed-stage startups.
• Sector emphasis on healthcare services and healthcare technology, specifically pharma services and value-based care delivery.
• Operates within Athyrium's broader mandate: royalties, structured credit, equity, and special situations across biotech, pharma, healthcare services, healthcare IT, and medical devices/products.
• Backs companies globally through large, structured capital commitments drawn from funds with $4.6B+ in committed capital, rather than small angel checks.